Patient-Specific Planning for Thermal Magnetic Resonance of Glioblastoma Multiforme.
EMF simulations
RF applicator
glioblastoma multiforme
patient-specific therapy planning
radiofrequency hyperthermia
thermal magnetic resonance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Apr 2021
14 Apr 2021
Historique:
received:
31
01
2021
revised:
26
03
2021
accepted:
02
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Thermal intervention is a potent sensitizer of cells to chemo- and radiotherapy in cancer treatment. Glioblastoma multiforme (GBM) is a potential clinical target, given the cancer's aggressive nature and resistance to current treatment options. This drives research into optimization algorithms for treatment planning as well as radiofrequency (RF) applicator design for treatment delivery. In this work, nine clinically realistic GBM target volumes (TVs) for thermal intervention are compared using three optimization algorithms and up to ten RF applicator designs for thermal magnetic resonance. Hyperthermia treatment planning (HTP) was successfully performed for all cases, including very small, large, and even split target volumes. Minimum requirements formulated for the metrics assessing HTP outcome were met and exceeded for all patient specific cases. Results indicate a 16 channel two row arrangement to be most promising. HTP of TVs with a small extent in the cranial-caudal direction in conjunction with a large radial extent remains challenging despite the advanced optimization algorithms used. In general, deep seated targets are favorable. Overall, our findings indicate that a one-size-fits-all RF applicator might not be the ultimate approach in hyperthermia of brain tumors. It stands to reason that modular and reconfigurable RF applicator configurations might best suit the needs of targeting individual GBM geometry.
Identifiants
pubmed: 33919701
pii: cancers13081867
doi: 10.3390/cancers13081867
pmc: PMC8070230
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Horizon 2020
ID : 743077
Références
Strahlenther Onkol. 1989 Oct;165(10):700-4
pubmed: 2814805
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443246
Magn Reson Med. 2004 May;51(5):913-23
pubmed: 15122673
PLoS One. 2013 Apr 22;8(4):e61661
pubmed: 23613896
Drug Deliv. 2019 Dec;26(1):551-565
pubmed: 31928355
Int J Hyperthermia. 2018 Feb;34(1):87-100
pubmed: 28540815
Int J Hyperthermia. 1990 May-Jun;6(3):479-86
pubmed: 2198311
Cancers (Basel). 2020 Apr 25;12(5):
pubmed: 32344914
Phys Med Biol. 2018 Dec 21;64(1):015013
pubmed: 30523869
Magn Reson Med. 2011 Nov;66(5):1468-76
pubmed: 21604294
Radiother Oncol. 2011 Apr;99(1):44-8
pubmed: 21458093
Anticancer Res. 2014 Feb;34(2):565-74
pubmed: 24510985
Integr Cancer Ther. 2019 Jan-Dec;18:1534735418812691
pubmed: 30580645
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):365-75
pubmed: 9457823
Int J Hyperthermia. 1996 Jul-Aug;12(4):477-94
pubmed: 8877472
J Ther Ultrasound. 2014 Oct 16;2:17
pubmed: 25671132
Int J Hyperthermia. 2007 Nov;23(7):567-76
pubmed: 18038287
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26
pubmed: 17493790
Int J Hyperthermia. 2009 Nov;25(7):593-608
pubmed: 19848621
NMR Biomed. 2020 May;33(5):e4274
pubmed: 32078208
Int J Hyperthermia. 2020;37(1):549-563
pubmed: 32484019
Radiother Oncol. 2016 Jan;118(1):35-42
pubmed: 26777122
Int J Hyperthermia. 2017 Jun;33(4):387-400
pubmed: 28064557
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31600958
Cancers (Basel). 2020 May 27;12(6):
pubmed: 32471299
Int J Hyperthermia. 2017 Jun;33(4):378-386
pubmed: 27951733
Int J Hyperthermia. 2016;32(1):63-75
pubmed: 26708630
Radiat Oncol. 2016 Feb 11;11:21
pubmed: 26868027
Drug Des Devel Ther. 2015 Apr 09;9:2089-100
pubmed: 25926719
Radiother Oncol. 2020 Jan;142:43-51
pubmed: 31431370
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95
pubmed: 9457811
Strahlenther Onkol. 2013 Jan;189(1):74-80
pubmed: 23161121
Int J Hyperthermia. 2015 May;31(3):302-9
pubmed: 25367011
Phys Med Biol. 2016 Jul 01;61(14):5406-5425
pubmed: 27367651
Magn Reson Med. 2016 Jan;75(1):381-9
pubmed: 25752920
Int J Hyperthermia. 2018 Sep;34(6):714-730
pubmed: 29509043
Int J Hyperthermia. 2018 Dec;34(8):1316-1328
pubmed: 29353516
Phys Med Biol. 2010 May 7;55(9):2465-80
pubmed: 20371911
Phys Med Biol. 2008 Dec 7;53(23):6799-820
pubmed: 19001699
Phys Med Biol. 2003 Oct 7;48(19):3143-55
pubmed: 14579857
ACS Chem Neurosci. 2019 Mar 20;10(3):1157-1172
pubmed: 30715851
IEEE Trans Biomed Eng. 1984 Jan;31(1):106-14
pubmed: 6724597
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1039-1047
pubmed: 28870786
Magn Reson Med. 2018 Nov;80(5):2246-2255
pubmed: 29607551
MAGMA. 2016 Jun;29(3):641-56
pubmed: 27097905
Int J Hyperthermia. 2005 Sep;21(6):515-31
pubmed: 16147437
J Clin Invest. 2010 Nov;120(11):3760-72
pubmed: 21041958
Magn Reson Med. 2015 Oct;74(4):1165-76
pubmed: 25324179
Cancers (Basel). 2020 Jun 28;12(7):
pubmed: 32605322
Magn Reson Med. 1994 Sep;32(3):358-69
pubmed: 7984068
Cancers (Basel). 2021 Feb 28;13(5):
pubmed: 33670862
Int J Hyperthermia. 2019;36(1):456-465
pubmed: 30973030